Dosing Tacrolimus Based on CYP3A5 Genotype: Will It Improve Clinical Outcome?

DA Hesselink - Clinical Pharmacology & Therapeutics, 2010 - Wiley Online Library
Tacrolimus, widely used to prevent acute rejection following solid‐organ transplantation, has
become the cornerstone of immunosuppressive therapy after kidney transplantation. More …
被引用次数：52 相关文章

Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?

T van Gelder, DA Hesselink - Clinical pharmacology and …, 2010 - pubmed.ncbi.nlm.nih.gov
Tacrolimus, widely used to prevent acute rejection following solid-organ transplantation, has
become the cornerstone of immunosuppressive therapy after kidney transplantation. More …
[PDF] researchgate.net

[PDF][PDF] Dosing Tacrolimus Based on CYP3A5Genotype: Will It Improve Clinical Outcome?

T van Gelder, DA Hesselink - CliniCal pharMaCology & …, 2010 - researchgate.net
Tacrolimus, widely used to prevent acute rejection following solid-organ transplantation, has
become the cornerstone of immunosuppressive therapy after kidney transplantation. More …

Dosing tacrolimus based on CYP3A5 genotype: Will it improve clinical outcome?

T van Gelder, D Hesselink - Clinical Pharmacology and Therapeutics, 2010 - repub.eur.nl
Tacrolimus, widely used to prevent acute rejection following solid-organ transplantation, has
become the cornerstone of immunosuppressive therapy after kidney transplantation. More …

Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?

T van Gelder, DA Hesselink - Clinical Pharmacology and …, 2010 - europepmc.org
Tacrolimus, widely used to prevent acute rejection following solid-organ transplantation, has
become the cornerstone of immunosuppressive therapy after kidney transplantation. More …